Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 41 | 44 | 48 | 61 | 85 | 99 | 94 | 94 | 149 | 170 | |
| COGS | — | -4 | -27 | -29 | -35 | 37 | 42 | 43 | 47 | 76 | 87 |
| Gross profit | — | — | — | — | — | 47 | 58 | 51 | 46 | 73 | 84 |
| 38 | 38 | 63 | 71 | 88 | 29 | 34 | 32 | 29 | 47 | 57 | |
| 4 | 6 | 7 | 5 | 8 | 19 | 23 | 19 | 17 | 26 | 26 | |
| OPM % | 10.5% | 15.6% | 16% | 11.4% | 13.9% | 22.1% | 23.4% | 20.4% | 18.1% | 17.7% | 15.4% |
| Depreciation | — | — | — | — | — | 6 | 5 | 5 | 5 | 9 | 12 |
| Interest | — | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 6 |
| 1 | 1 | 1 | 4 | — | 0 | 2 | 2 | 2 | 2 | 1 | |
| Profit before tax | 4 | 5 | 6 | 9 | 9 | 13 | 19 | 15 | 10 | 14 | 9 |
| Tax | 1 | 2 | 1 | -0 | -0 | -0 | -0 | -0 | 2 | -0 | 1 |
| Tax % | 33.3% | 33.2% | 18.8% | -2.9% | -0.5% | -1.1% | -2.6% | -3.4% | 14.9% | -2.5% | 13.9% |
| 3 | 3 | 5 | 9 | 9 | 13 | 19 | 15 | 9 | 14 | 8 | |
| PAT margin % | 6.3% | 8.1% | 11.9% | 18.6% | 14.4% | 14.9% | 19.5% | 16.1% | 9.2% | 9.3% | 4.8% |
| EPS (₹) | 7.8 | 9.6 | 14.6 | 8 | 6.4 | 8.1 | — | 10.4 | 5.6 | 8.8 | 5.2 |
| EPS adjusted (₹) | — | — | — | — | — | 9.2 | 13.4 | 10.4 | 5.5 | 8.8 | 5.2 |
| 0% | 10.4% | 3.4% | 6.3% | 3.9% | 6.2% | — | 4.8% | 8.9% | 5.7% | 9.6% | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 7 | 7 | 7 | 8 | 8 | 8 |
| Reserves | 173 | 266 | 284 | 366 | 390 | 397 |
| Minority interest | — | 0 | 0 | — | — | — |
| 11 | 14 | 34 | 45 | 61 | 66 | |
| 31 | 30 | 40 | 52 | 53 | 57 | |
| Total equity & liabilities | 223 | 318 | 365 | 471 | 512 | 528 |
| 120 | 128 | 126 | 122 | 250 | 250 | |
| CWIP | 0 | 3 | 57 | 117 | — | — |
| Investments | 53 | 55 | 65 | 73 | 74 | 81 |
| 49 | 131 | 117 | 159 | 188 | 197 | |
| Total assets | 223 | 318 | 365 | 471 | 512 | 528 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 46 | 7 | -13 | 0 | -1 | -1 | |
| -61 | -17 | -65 | -80 | -20 | -18 | |
| 10 | 76 | 21 | 93 | 22 | -2 | |
| Net cash flow | -5 | 66 | -57 | 13 | 1 | -21 |
| Free cash flow | -1 | -9 | -69 | -72 | -22 | -20 |
| CFO / Operating profit % | 245.6% | 30.3% | -66.4% | 2.8% | -4% | -4.8% |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Agrochemicals | 151.26 | 22.02 | 317.12 | 59.78 | 257.34 | 8.56 |
| Unallacated other operating revenue | 9.93 | 0 |
| 0 |
| 0 |
| — |
| — |
| Active Pharma Ingredient (API) | 9.05 | -6.43 | 125.69 | 12.1 | 113.59 | -5.66 |
| Pharma Formulation | 0 | 0 | 0 | 0 | — | — |
₹ crore by fiscal year